In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…
Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
A study of nintedanib in patients with ILD associated with systemic sclerosis showed the treatment had only limited improvement. Although these patients had a lower rate of decline in forced vital capacity than those on placebo, nintedanib did not result in clinical benefits for other manifestations of systemic sclerosis…
Democrats Clash on Healthcare in Scrappy First U.S. Presidential Debate
MIAMI (Reuters)—Democratic presidential contenders battled over healthcare coverage and border policy on Wednesday during a surprisingly heated first debate that laid bare the party’s divisions on whether to abolish private insurance and shift to a Medicare-for-All system. In the first round of back-to-back debates, several of the lesser-known candidates vied for attention in the crowded…
Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
Adding certolizumab pegol to background medication is better than adding a placebo for patients with active nonradiographic axial spondyloarthritis, according to a new study…
Hot Topics, Fresh Formats: ACR/ARP Annual Meeting Clinical Session Preview
The clinical sessions at the 2019 ACR/ARP Annual Meeting feature cutting-edge techniques in rheumatology and enable attendees to hone new skills and explore medically relevant topics…
From Climbing Walls to In the Rheum: What’s New at the 2019 Annual Meeting?
This year, the Annual Meeting Planning Committee has designed an engaging program, bringing together the best experts to address important topics. Here’s a sneak peek at what’s new…
Basic Science Sessions: Diverse Topics, Wide Appeal
Machine learning, immunology, the metabolism—are just a few of the topics addressed during…
All in One Setting: Integrated Team-Based Care for Autoimmunity
Rheumatologists, behavioral specialists, pharmacists and other healthcare professionals are working in the Autoimmunity Institute at Allegheny Health Network, Pittsburgh, to care for the whole patient…
Tanezumab’s Phase 3 Results for OA
In a recent study, tanezumab proved safe and effective in the treatment of knee and hip osteoarthritis…
The Rescue: Moving RA Patients from Adalimumab to Baricitinib
The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…
- « Previous Page
- 1
- …
- 257
- 258
- 259
- 260
- 261
- …
- 816
- Next Page »